Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PVLA
Stock Latest News
TipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
3d ago
PTN
CRNX
Premium
Ratings
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
4d ago
PVLA
Premium
Ratings
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
4d ago
PVLA
Premium
The Fly
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
4d ago
PVLA
Premium
The Fly
Palvella Therapeutics selloff a buying opportunity, says BTIG
4d ago
PVLA
Premium
The Fly
Palvella Therapeutics falls -13.6%
5d ago
PVLA
Premium
The Fly
Palvella Therapeutics falls -9.0%
5d ago
PVLA
Premium
The Fly
Ligand price target raised to $345 from $330 at Craig-Hallum
5d ago
SNY
LGND
Premium
Company Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
10d ago
8K
PVLA
Premium
Company Announcements
Palvella Therapeutics Adds Industry Veteran to Board
25d ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
25d ago
PVLA
SVRA
Premium
The Fly
Palvella submits first rolling new drug application to FDA for Qtorin
26d ago
PVLA
Premium
The Fly
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
1M ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
1M ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
2M ago
PVLA
Premium
Ratings
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
2M ago
PVLA
Premium
Ratings
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
2M ago
PVLA
Premium
Company Announcements
Palvella Reports Positive Phase 3 Data for QTORIN
2M ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics announces new data from SELVA, TOIVA studies
2M ago
PVLA
Premium
Company Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
2M ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
2M ago
PVLA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
